NMRD

Nemaura Medical Announces Fiscal Second Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
Monday, November 15, 2021
Metabolism, NMRD, Type 2 diabetes, CGM, PMA, CEO, Technology, Sumathi Best Television Current Reporting Award, Food, Prediabetes, Harvard Medical School, CE, Insurance, Diabetes, Artificial intelligence, Research, Advertising, Total, Annual report, Type 2, Company, Regulation of tobacco by the U.S. Food and Drug Administration, GLOBE, U.S. Securities and Exchange Commission, Weight loss, Marketing, Nasdaq, Patient, Skin, FDA, Medical device, Pharmaceutical industry

Loughborough, England, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD) (Nemaura or the Company), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today provides a business update and releases its financial results for the second quarter of fiscal 2022 (for the three months ended September 30, 2021).

Key Points: 
  • Loughborough, England, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD) (Nemaura or the Company), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today provides a business update and releases its financial results for the second quarter of fiscal 2022 (for the three months ended September 30, 2021).
  • Launched beta version of Miboko, its mass-market metabolic health program utilizing the Companys non-invasive glucose sensor along with an AI mobile application.
  • Dr. Hamdy is a senior endocrinologist at the Joslin Diabetes Centre, and associate professor of Medicine at Harvard Medical School.
  • Nemaura Medical Inc. is a medical technology company developing and commercializing non-invasive wearable diagnostic devices.

Nemaura Medical to Present at the Diabetes Technology Society 2021 Conference on November 4, 2021

Retrieved on: 
Wednesday, November 3, 2021
2021 Essex County Council election, Q & A, NMRD, Diabetes Technology Society, CGM, NASDAQ, FDA, Prediabetes, Weight loss, Nemaura Medical, Company, CE, Diabetes, Artificial intelligence, PMA, GLOBE, Pharmaceutical industry, Medical device

To watch the presentation, participants must be registered for the conference, which can be found here.

Key Points: 
  • To watch the presentation, participants must be registered for the conference, which can be found here.
  • The Diabetes Technology Society meetings goal is to connect technology developers and users to facilitate the creation of new and cost-effective tools to help people with diabetes.
  • The format will include state-of-the-art lectures, oral presentations of abstracts, panel discussions with Q & A sessions, and virtual poster sessions.
  • Nemaura Medical Inc. is a medical technology company developing and commercializing non-invasive wearable diagnostic devices.

Nemaura Medical to Present at the LD Micro Main Event Conference

Retrieved on: 
Tuesday, October 5, 2021
Artificial intelligence, Weight loss, PMA, Conference, NASDAQ, Nemaura Medical, NMRD, Diabetes, Company, CE, Prediabetes, CGM, GLOBE, Pharmaceutical industry, Medical device

Loughborough, England, Oct. 05, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, announces today that Chief Executive Officer Faz Chowdhury, Ph.D. will be presenting virtually at the 14th Annual LD Micro Main Event Conference.

Key Points: 
  • Loughborough, England, Oct. 05, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, announces today that Chief Executive Officer Faz Chowdhury, Ph.D. will be presenting virtually at the 14th Annual LD Micro Main Event Conference.
  • Dr. Chowdhury will deliver his corporate presentation on October 13 at 10:00 AM ET.
  • Nemaura Medical Inc. is a medical technology company developing and commercializing non-invasive wearable diagnostic devices.
  • Nemaura has submitted a PMA (Premarket Approval Application) for sugarBEAT to the U.S. FDA.

Nemaura Medical Launches Beta Version of Its Metabolic Health Program

Retrieved on: 
Wednesday, September 29, 2021
Dementia, Artificial intelligence, Weight loss, Food, Health, PMA, Conference, NASDAQ, Population, Nemaura Medical, AI, Metabolism, NMRD, Diabetes, Â, Company, Human, Program, Eating, Technology, CE, Appetite, Obesity, Insulin resistance, Habit, Prediabetes, CGM, GLOBE, Medical device, Pharmaceutical industry

LOUGHBOROUGH, England, Sept. 29, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or “the Company”), a medical technology company focused on developing and commercializing noninvasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, announces the beta launch of MiBoKo, a new metabolic health program utilizing a noninvasive glucose sensor along with an AI mobile application.

Key Points: 
  • Those with prediabetes or obesity concerns, or even those looking to maintain better health through more careful glucose control, could benefit from such a metabolic health program.
  • A user can find out how well their body responds to sugar through their metabolic health score and how what they eat and what they do every day uniquely affects their metabolic health.
  • We believe that MiBoKo offers insights into metabolic health in a user-friendly way unlike any other program on the market.
  • There is no cost during the beta period, with approved MiBoKo beta testers receiving the sensors and AI program free of charge.

Nemaura Medical Inc. (NASDAQ: NMRD) Diabetes, Obesity Solutions Differentiated in Form and Function

Retrieved on: 
Friday, September 24, 2021
Social media, News, Artificial intelligence, PMA, BEAT, Solution, SMS, World, NASDAQ, Death, World Health Organization, NNW, Heart, NMRD, Diabetes, Nemaura Medical, Overload, IIB, Blood, Prediabetes, CGM, GLOBE, Pharmaceutical industry, Medical device

Data from the World Health Organization shows that diabetes kills about 3.4 million people worldwide each year.

Key Points: 
  • Data from the World Health Organization shows that diabetes kills about 3.4 million people worldwide each year.
  • Nemaura Medical Inc. (NASDAQ: NMRD ) has spent the last decade developing the worlds first daily-wear, noninvasive glucose sensor and integrated healthcare app.
  • The companys BEAT(R) diabetes platform, inclusive of sugarBEAT(R) CGM and proBEAT(TM), which combines noninvasive glucose data processed using artificial intelligence (AI) and a digital healthcare subscription service, is clearly differentiated from others in form and function.
  • Nemaura Medical is a medical technology company developing and commercializing non-invasive wearable diagnostic devices.

Nemaura Medical Inc. (NASDAQ: NMRD) Offers Sought-After Solutions in Areas of Unmet Medical Need

Retrieved on: 
Wednesday, September 22, 2021
Adoption, Social media, News, Artificial intelligence, Exorbitant privilege, PMA, BEAT, Solution, SMS, NASDAQ, NNW, GDP, NMRD, Diabetes, Industry, Nemaura Medical, Awareness, Association of British HealthTech Industries, Overload, COVID-19, Technology, Plague, IIB, Prediabetes, Medtech, CGM, GLOBE, Pharmaceutical industry

Safe to say, the industry is looking for solutions, particularly more efficient ones that improve health outcomes and lower direct and indirect costs.

Key Points: 
  • Safe to say, the industry is looking for solutions, particularly more efficient ones that improve health outcomes and lower direct and indirect costs.
  • The answer is found in technology, with healthtech (healthcare technology) and medtech (medical technology) buzzwords speaking to leveraging next-generation innovation in a bid to flatten the healthcare spending curve.
  • Some companies, such as Nemaura Medical Inc. (NASDAQ: NMRD), are specializing in certain areas of unmet medical need, such as diabetes and obesity.
  • Nemaura Medical is a medical technology company developing and commercializing noninvasive wearable diagnostic devices.

Nemaura Medical to Present at the Benzinga Healthcare Small Cap Conference

Retrieved on: 
Tuesday, September 21, 2021
Artificial intelligence, Weight loss, PMA, Conference, NASDAQ, Nemaura Medical, NMRD, Diabetes, Company, CE, Prediabetes, CGM, GLOBE, Medical device

Loughborough, England, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, announces today that Chief Executive Officer Faz Chowdhury, Ph.D. will present at the Benzinga Healthcare Small Cap Conference, which is being held virtually from September 29 30, 2021.

Key Points: 
  • Loughborough, England, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, announces today that Chief Executive Officer Faz Chowdhury, Ph.D. will present at the Benzinga Healthcare Small Cap Conference, which is being held virtually from September 29 30, 2021.
  • Dr. Chowdhury will deliver his corporate presentation on September 29 at 11:10 AM ET.
  • Investors can register for the conference here: https://www.benzinga.com/events/small-cap/healthcare/
    Nemaura Medical Inc. is a medical technology company developing and commercializing non-invasive wearable diagnostic devices.
  • Nemaura has submitted a PMA (Premarket Approval Application) for sugarBEAT to the U.S. FDA.

Nemaura Medical to Present at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference

Retrieved on: 
Wednesday, September 1, 2021
Company, PMA, CGM, NMRD, GLOBE, Diabetes, Artificial intelligence, CE, Nemaura Medical, NASDAQ, Prediabetes, Conference, Weight loss, Medical device

Loughborough, England, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, announces today that Chief Executive Officer Faz Chowdhury, Ph.D. will present at the H.C. Wainwright 23rd Annual Global Investment Conference, which is being held virtually from September 13 15, 2021.

Key Points: 
  • Loughborough, England, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, announces today that Chief Executive Officer Faz Chowdhury, Ph.D. will present at the H.C. Wainwright 23rd Annual Global Investment Conference, which is being held virtually from September 13 15, 2021.
  • Dr. Chowdhury will deliver his corporate presentation, which will become available beginning on September 13 at 7:00 AM ET.
  • Mr. Chowdhury will also be available for one-on-one meetings throughout the conference.
  • Nemaura Medical Inc. is a medical technology company developing and commercializing non-invasive wearable diagnostic devices.

Nemaura Medical Reports Financial Results and Provides Business Update for the First Fiscal Quarter Ended June 30, 2021

Retrieved on: 
Monday, August 16, 2021
CE, Prediabetes, CEO, Diabetes, Obesity, CTM, Company, Food, CGM, Sumathi Best Television Current Reporting Award, GLOBE, Total, U.S. Securities and Exchange Commission, NMRD, Research, PMA, FDA, Marketing, Regulation of tobacco by the U.S. Food and Drug Administration, Skin, Patient, Annual report, Exercise, Artificial intelligence, Nasdaq, Type 2 diabetes, Weight loss, Medical device, Pharmaceutical industry

Loughborough, England, Aug. 16, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD) (Nemaura or the Company), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today provides a business update and releases its financial results for the first fiscal quarter, ended June 30, 2021, of fiscal 2022.

Key Points: 
  • Loughborough, England, Aug. 16, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD) (Nemaura or the Company), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today provides a business update and releases its financial results for the first fiscal quarter, ended June 30, 2021, of fiscal 2022.
  • Cash and cash equivalents at June 30, 2021 were $31.3 million, as compared to $31.9 million at March 31, 2021.
  • Proceeds were received from the exercise of 366,892 warrants during the quarter ended June 30, 2021, amounting to $3 million.
  • Nemaura Medical Inc. is a medical technology company developing and commercializing non-invasive wearable diagnostic devices.